QSAR Studies of 3-(4-(3-(Substitutedphenyl) Acryloyl) Phenyl)-2-Substituted phenyl/Phenylthiazolidin-4-ones for Anticancer Activity

Authors

  • Ruchika Goyal Drug Discovery and Research Laboratory, Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar, Haryana, India
  • Ashwani Kumar Drug Discovery and Research Laboratory, Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar, Haryana, India
  • Sunil Kumar Drug Discovery and Research Laboratory, Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar, Haryana, India
  • Sandeep Jain Drug Discovery and Research Laboratory, Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar, Haryana, India
  • Parvin Kumar Department of Chemistry, Kurukshetra University, Kurukshetra, Haryana, India

Abstract

Both, Chalcone and 4-thiazolidinone, are therapeutically significant organic moieties with anticancer activities. QSAR (Quantitative structure–activity relationship) studies of ten synthesized chalcone-thiazolidinone hybrids have been described for anticancer activity against three cancer cell lines: A-549 (Human lung adenocarcinoma), U-87 MG (Human glioblastoma cancer cells) and COLO-205 (Human colon cancer cells). The developed linear QSAR models have significant statistical quality showing good fitting ability and robustness. The Q2 and R2 values of all the described models were more than 0.5 which corroborated the internal predictive ability of the resultant QSAR equations. Wlambda3.mass, SC-3, FNSA-3, BCUTp-1l, Wlambda1.unity descriptors were imperative in elucidation of anticancer activity trends.

Keywords: Chalcone-thiazolidinone hybrids, anticancer activity, cell lines, QSAR

Cite this Article

Ashwani Kumar, Ruchika Goyal, Sunil Kumar et al. Qsar Studies of 3-(4-(3-(Substitutedphenyl) Acryloyl) Phenyl)-2-Substituted Phenyl/Phenylthiazolidin-4-Ones for Anticancer Activity. Research & Reviews: A Journal of Drug Design & Discovery. 2016; 3(3): 16–22p.

Downloads

Published

2019-03-04

Issue

Vol. 3 No. 3 (2016)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.